[soccertese]

http://medicalxpress.com/news/2011-0...ease-drug.html

[lindylanka]

Is someone able to translate this to simple language?
I'd like to understand how this is working and which kind of patients it would benefit if it made it through the translational phase........

[LindaH]

The sponsor NeuroNova has some info on their web site. There is a Fact Sheet at
http://www.neuronova.com/images/pdf/...031_091126.pdf


Also see clinicaltrials.gov
A phase II trial is starting this year. Two trial centers are listed, both in Sweden, so far. It is for “moderately severe” pwp. See
http://clinicaltrials.gov/ct2/show/N...snn0031&rank=1

And the parkinson pipeline project ‘s data base has been tracking this treatment. See
http://pdpipeline.org/ . Click on Therapy Development Database. Look for SNN0031 on the Scorecard.

From sponsor’s website:
“sNN0031 is a novel drug candidate for the treatment of moderate to severe stage Parkinson’s disease that is designed to act on neural stem and progenitor cells in the brain. In animal models of Parkinson’s disease, treatment with sNN0031 restores motor function and improves neurochemical deficits. The product is comprised of the naturally occurring protein PDGF-BB (platelet-derived growth factor BB) formulated for intracerebroventricular (ICV) delivery. The intended therapy involves short-term continuous infusion of sNN0031 into the ventricular lumen, in order to optiŽmize PDGF-BB access to the lateral ventricular walls of the brain where the targeted stem and progenitor cells reside. sNN0031 holds the potential to halt and even reverse disease progression, a much-needed improveŽment over currently available treatments, which only address the symptoms of Parkinson’s disease.”

BTW, Medtronic is a co-sponsor of the phase II trial

[lindylanka]

Thanks Linda, that helps........

Lindy